Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for Myeloprotection in Advanced Solid Tumors
NCT06297811Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in myelosuppression, sponsored by Sun Yat-sen University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT06297811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297811.